Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer

July 7th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.

Expert Discusses Recent Endometrial Cancer Research

June 23rd 2017

Rebecca C. Arend, MD, discusses highlights from the ASCO meeting and other key developments in endometrial cancer.

Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

June 20th 2017

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Lurbinectedin Shows Promise in Endometrial Cancer

June 18th 2017

Lurbinectedin (PM01183) induced a high rate of response as monotherapy and with doxorubicin or paclitaxel in patients with advanced endometrial cancer.

Dr. Leath on Ongoing Trials for Endometrial Cancer

June 9th 2017

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses ongoing trials for patients with endometrial cancer.

Dr. Arend on Personalized Medicine for Endometrial Cancer

June 9th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.

Pembrolizumab Demonstrates Durable Response in PD-L1+ Endometrial Cancer

May 30th 2017

Results from the KEYNOTE-028 study showed that pembrolizumab (Keytruda) was associated with a median duration of response of 6 months and a 6-month progression-free survival rate of 40.4% in women with advanced PD-L1–positive endometrial cancer.

Dr. Wingo on Advances of Surgical Technology in Gynecologic Cancers

May 25th 2017

Shana Wingo, MD, gynecologic oncology, Arizona Oncology, discusses the advances of surgical technology in gynecologic cancers.

Dr. Chase Discusses Risk Factors in Gynecologic Cancers

May 23rd 2017

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologist oncologist with Arizona Oncology, discusses the risk factors in gynecologic cancers.

Study Warns Women of Premature Discontinuation of Cervical Cancer Screening

May 16th 2017

Mary C. White, ScD, MPH, discusses the unmet needs near and after the stopping age for cervical cancer screening.

Dr. Beddoe on the Impact of Cervical Cancer Screening

May 11th 2017

Ann Marie Beddoe, MD, assistant professor of Obstetrics, Gynecology and Reproductive Science, Mount Sinai Hospital, discusses the impact of cervical cancer screening for women in the United States.

Zoptarelin Doxorubicin Falls Short in Phase III Endometrial Cancer Trial

May 5th 2017

Zoptarelin doxorubicin (Zoptrex), a hybrid molecule combining an LHRH-agonist and doxorubicin, failed to improve median overall survival in a phase III advanced endometrial cancer trial, according to the manufacturer of the treatment, Aeterna Zentaris.

Bariatric Surgery Associated With Reduced Risk for Female-specific Cancers

May 4th 2017

Women who underwent bariatric surgery to combat obesity were less likely to develop any cancer and female-specific cancers, as demonstrated in results published in Gynecologic Oncology.

Dr. Klopp on IMRT for Gynecologic Cancers

May 3rd 2017

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center discusses intensity-modulated radiation therapy (IMRT) for patients with gynecologic cancers.

Expert Addresses Issues in Advanced Gynecologic Cancers

April 26th 2017

Dana Chase, MD, discusses obstacles to progress and her hope for the future in advanced gynecologic cancers.

Minimally Invasive Surgery Increasingly Used in Gynecologic Malignancies

April 24th 2017

Shana Wingo, MD, discusses the advancements being made in the field of surgery for patients with gynecologic cancers.

Dr. Chase on Challenges Facing Gynecologic Cancers

April 19th 2017

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses challenges facing gynecologic cancers.

Dr. Monk on Immunotherapy for Gynecologic Cancer

April 19th 2017

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.

Dr. Dalton on Novel Approaches in Uterine Cancer

April 19th 2017

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.

Dr. Wingo on Surgical Approaches Across Gynecologic Malignancies

April 12th 2017

Shana Wingo, MD, gynecologic oncology, Arizona Oncology, discusses the various surgical approaches being explored and conducted across patients with gynecologic malignancies.